Belite Bio (BLTE) H.C. Wainwright 4th Annual Ophthalmology Virtual Conference summary

Conference overview

• The event was the H.C. Wainwright Fourth Annual Ophthalmology Virtual Conference, featuring presentations on clinical advancements and market opportunities in ophthalmology.

• The main focus was on the development of Tinlarebant, an oral therapy targeting Stargardt disease and geographic atrophy (GA), both linked to toxic vitamin A byproducts.

• Tinlarebant is in phase III trials for both indications, with studies spanning the U.S., Japan, and the U.K., and has received multiple regulatory designations, including Fast Track and orphan drug status.

• The company highlighted a strong patent portfolio, with key patents extending to at least 2040.

Clinical development and trial updates

• Phase II trial in adolescent Stargardt patients showed promising safety and efficacy, with an 80% reduction in RBP4 and stabilization of vision in most subjects.

• The DRAGON phase III study for Stargardt disease is halfway through, with interim analysis expected in Q4 this year; DRAGON2 may enable early approval in Japan.

• The PHOENIX phase III study for GA is recruiting, aiming for 429 subjects, with enrollment expected to close by Q1 next year and interim analysis in Q1 2026.

• Tinlarebant’s mechanism targets RBP4, reducing vitamin A delivery to the eye and thus toxic byproduct accumulation.

Mechanism of action and disease insights

• Tinlarebant binds RBP4 with high affinity, preventing vitamin A transport to the eye and reducing bisretinoid buildup, which is central to disease progression in Stargardt and GA.

• Early intervention is emphasized as critical, as it targets disease before retinal inflammation complicates management.

• Clinical imaging shows that autofluorescent bisretinoid zones predict future atrophy, supporting the therapeutic rationale.